Last reviewed · How we verify
NCT03998111
Genetic Variation in CLTCL1 and Whole-body Glucose Control
NA trial testing Oral glucose tolerance test in Glucose Control in 82 participants. Completed in 1 March 2022.
1 February 2022
Quick facts
| Lead sponsor | Javier Gonzalez |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 82 |
| Start date | 1 October 2018 |
| Primary completion | 1 February 2022 |
| Estimated completion | 1 March 2022 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Oral glucose tolerance test — full drug profile →
Conditions studied
- Glucose Control — all drugs for Glucose Control →
Sponsor
Javier Gonzalez
Who can join
Adults 18 to 65, any sex, with Glucose Control. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Maintaining stable blood glucose concentrations after eating has important implications for health. Individuals who are better able to maintain stable blood glucose concentrations after consuming carbohydrate have a lower risk of mortality from cardiovascular disease. Muscle is the primary tissue for glucose disposal following a meal, and responsiveness of this tissue to insulin is dictated by GLUT4 translocation to the muscle cell membrane. Clathrin heavy chain isoform 22 (CHC22) is a protein that plays a key role in intracellular GLUT4 action, and it may play an important role in whole-body glucose control. Genetic variation in the gene which codes for CHC22 may be able to explain differences in glucose control at the whole-body level.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03998111
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Oral glucose tolerance test
Trials testing the same drug.
- NCT06396871 — Deep Phenotyping of Peripheral Blood Cells and Circulating Factors in Metabolic Diseases · recruiting
- NCT05568134 — Alternate Measures of Glucose During OGTT Testing for CFRD · completed
- NCT05765123 — Gastric Emptying Validation Pilot Study (MRI Val) · completed
- NCT05316038 — Metabolic and Infectious Complications Post Belatacept Conversion · unknown
- NCT05310292 — A Glucometabolic Evaluation of Patients With Idiopathic Ketotic Hypoglycemia · NA · unknown
Other recruiting trials for Glucose Control
Currently open trials in the same condition.
- NCT06640179 — Feasibility and Plausible Effectiveness of a Lifestyle Intervention in Kidney Transplant Recipients (HEAL) · NA · recruiting
- NCT06273631 — Effect of Changes in Carbohydrate Intake Patterns on Glucose Control in Patients with Type 1 Diabetes · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03998111 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Javier Gonzalez
- Last refreshed: 4 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03998111.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing